P
Prabir Chakraborti
Researcher at Royal Derby Hospital
Publications - 19
Citations - 3514
Prabir Chakraborti is an academic researcher from Royal Derby Hospital. The author has contributed to research in topics: Docetaxel & Zoledronic acid. The author has an hindex of 12, co-authored 18 publications receiving 2626 citations. Previous affiliations of Prabir Chakraborti include Derby Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James,Nicholas D. James,Matthew R. Sydes,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Chris Parker,J. Martin Russell,Gerhardt Attard,Johann S. de Bono,William Cross,Robert Jones,George N. Thalmann,Claire Amos,David Matheson,Robin Millman,Mymoona Alzouebi,Sharon Beesley,Alison Birtle,Susannah Brock,Richard Cathomas,Prabir Chakraborti,Simon Chowdhury,Audrey Cook,Tony Elliott,Joanna Gale,Stephanie Gibbs,John Graham,J. Hetherington,Robert Hughes,Robert W. Laing,Fiona McKinna,Duncan McLaren,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Rajaguru Srinivasan,John Staffurth,Santhanam Sundar,Shaun Tolan,David Tsang,John Wagstaff,Mahesh K.B. Parmar +47 more
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
Journal ArticleDOI
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Journal ArticleDOI
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Alison Birtle,Alison Birtle,Mark Johnson,John D. Chester,Robert Jones,David Dolling,Richard T. Bryan,Chris Harris,Andrew Winterbottom,Anthony Blacker,James W.F. Catto,Prabir Chakraborti,Jenny L Donovan,Paul Anthony Elliott,Ann French,Satinder Jagdev,Benjamin Jenkins,Francis X. Keeley,Roger Kockelbergh,Thomas Powles,John Wagstaff,Caroline Wilson,Rachel Todd,Rebecca Lewis,Emma Hall +24 more
TL;DR: Gemcitabine–platinum combination chemotherapy initiated within 90 days after nephroureterectomy significantly improved disease-free survival in patients with locally advanced UTUC in a phase 3, open-label, randomised controlled trial.
Journal ArticleDOI
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Matthew R. Sydes,Melissa R. Spears,Malcolm David Mason,Noel W. Clarke,David P. Dearnaley,J.S. de Bono,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Silke Gillessen,Zafar Malik,Robert Jones,Robert Jones,Chris Parker,Chris Parker,A.W.S. Ritchie,J. M. Russell,J. M. Russell,Robin Millman,David Matheson,Claire Amos,Clare Gilson,A. Birtle,Susannah Brock,L. Capaldi,Prabir Chakraborti,Ananya Choudhury,Ananya Choudhury,L. Evans,Daniel Ford,Joanna Gale,Stephanie Gibbs,Duncan C. Gilbert,Robert Hughes,Duncan B. McLaren,Jason F. Lester,A. Nikapota,Joe M. O'Sullivan,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Sarah Rudman,R. Shaffer,D. Sheehan,Matthew S. Simms,Narayanan Srihari,Räto T. Strebel,Santhanam Sundar,Shaun Tolan,David Tsang,Mohini Varughese,John Wagstaff,Mahesh K.B. Parmar,Nicholas D. James +55 more
TL;DR: This direct, randomised comparative analysis of two new treatment standards for hormone-naïve prostate cancer showed no evidence of a difference in overall or prostate cancer-specific survival, nor in other important outcomes such as symptomatic skeletal events.
Journal ArticleDOI
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial
Nicholas D. James,Sarah Pirrie,Ann Pope,Darren Barton,Lazaros Andronis,Ilias Goranitis,Stuart Collins,Adam Daunton,Duncan McLaren,Joe M. O'Sullivan,Chris Parker,Emilio Porfiri,John Staffurth,Andrew Stanley,James D. Wylie,Sharon Beesley,Alison Birtle,Janet E. Brown,Prabir Chakraborti,Syed A. Hussain,Martin J. Russell,Lucinda Billingham +21 more
TL;DR: Clinical effectiveness and cost-effectiveness of combining docetaxel, ZA, and Sr89, all having palliative benefits and used in bony metastatic CRPC to control bone symptoms and, for docetAXel, to prolong survival were determined.